US 12,144,810 B1
Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
Michael Karl Bechtold, Macclesfield (GB); Julie Kay Cahill, Macclesfield (GB); Katja Maren Fastnacht, Macclesfield (GB); Kieran James Lennon, Macclesfield (GB); Bernd Harald Liepold, Macclesfield (GB); Claudia Bettina Packhaeuser, Macclesfield (GB); and Benedikt Steitz, Macclesfield (GB)
Assigned to KUDOS PHARMACEUTICALS LIMITED, Cambridge (GB)
Filed by KUDOS PHARMACEUTICALS LIMITED, Cambridge (GB)
Filed on Jul. 26, 2024, as Appl. No. 18/785,092.
Application 18/785,092 is a continuation of application No. 18/755,544, filed on Jun. 26, 2024.
Application 18/755,544 is a continuation of application No. 18/312,375, filed on May 4, 2023, granted, now 12,048,695.
Application 18/312,375 is a continuation of application No. 17/483,070, filed on Sep. 23, 2021, abandoned.
Application 17/483,070 is a continuation of application No. 16/863,074, filed on Apr. 30, 2020, abandoned.
Application 16/863,074 is a continuation of application No. 16/224,096, filed on Dec. 18, 2018, abandoned.
Application 16/224,096 is a continuation of application No. 15/707,376, filed on Sep. 18, 2017, abandoned.
Application 15/707,376 is a continuation of application No. 15/449,353, filed on Mar. 3, 2017, abandoned.
Application 15/449,353 is a continuation of application No. 14/688,326, filed on Apr. 16, 2015, abandoned.
Application 14/688,326 is a continuation of application No. 13/911,151, filed on Jun. 6, 2013, abandoned.
Application 13/911,151 is a continuation of application No. 12/574,801, filed on Oct. 7, 2009, granted, now 8,475,842, issued on Jul. 2, 2013.
Claims priority of provisional application 61/103,347, filed on Oct. 7, 2008.
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/502 (2006.01); A61K 9/14 (2006.01); A61K 9/20 (2006.01); A61K 47/02 (2006.01); A61K 47/12 (2006.01); A61K 47/20 (2006.01); A61K 47/32 (2006.01)
CPC A61K 31/502 (2013.01) [A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2027 (2013.01); A61K 9/2095 (2013.01); A61K 47/02 (2013.01); A61K 47/12 (2013.01); A61K 47/20 (2013.01); A61K 47/32 (2013.01)] 30 Claims
 
1. An immediate-release pharmaceutical composition in the form of a tablet comprising:
a solid dispersion comprising:
(i) 100 mg to 200 mg of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one (Compound 1); and
(ii) at least one polymer chosen from copovidone, povidone, hypromellose phthalate, hypromellose acetate succinate, 2-hydroxypropyl-β-cyclodextrin, hypromellose, polymethacrylates, hydroxypropyl cellulose, and cellulose acetate phthalate;
wherein the weight ratio of Compound 1 to the at least one polymer in the solid dispersion is in the range of from 1:1 to 1:9;
wherein the total concentration of Compound 1 in the tablet is in the range of from 10% by weight to 50% by weight; and
wherein the hardness of the tablet is greater than or equal to 25 N.